Need professional-grade analysis? Visit stockanalysis.com
$13.50B
14.40
671
4.16%
Tibet Rhodiola Pharmaceutical Holding Co (600211) trades on SHG in CNY. The company is classified in the Healthcare sector under the Drug Manufacturers - Specialty & Generic industry. The stock currently trades at CNY41.89, down 0.85% from the previous close.
Over the past year, 600211 has traded between a low of CNY35.50 and a high of CNY56.43. The stock has gained 14.1% over this period. It is currently 25.8% below its 52-week high.
Tibet Rhodiola Pharmaceutical Holding Co has a market capitalization of $13.50B, with a price-to-earnings ratio of 14.40 and a dividend yield of 4.16%.
Tibet Rhodiola Pharmaceutical Holding Co. produces and sells pharmaceutical products in China and internationally. The company offers modern Tibetan Medicines, including Nodikang capsules and granules, snow mountain golden arhat pain relief film, and ten-flavor Tida capsules; modern Chinese medicines, such as children Shuangqing granules, lipid clearing capsules, ginseng and zhi capsules, puyu capsules, and epilepsy flat film; and recombinant human brain natriuretic peptide for injection. It also provides isosorbide mononitrate sustained-release tablets; and oxygen rhodiola rosea moisturizing essence, secret recipe fragrance powder packet, rhodiola rosea, and Yuan Yang rhodiola rosea moisturizing essence products. In addition, the company offers biopharmaceuticals, traditional Chinese medicine, and chemical drugs for various fields, such as cardiovascular and cerebrovascular diseases, hepatobiliary diseases, orthopedic pain relief, rheumatism, and cold medicines. The company was founded in 1999 and is headquartered in Lhasa, China.
Side-by-side comparison against top Healthcare peers.